Nuclear projects demand precision, trust, and proven expertise. Element supports utilities, manufacturers, and engineering teams with testing and qualification services that keep systems safe, compliant, and ready to perform—delivering data-driven insight to meet regulations and extend asset life.

Learn More

Research & Applications

Astatine-211 targets blood-borne cancers in Seattle clinical trials

September 13, 2022, 9:30AMNuclear News
A clinical dose of At-211 is prepared at the University of Washington for use in a Fred Hutchison Cancer Center clinical trial. (Photo: UW/Don Hamlin)

Scientists in the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) are directly targeting cancerous cells traveling through patients’ bloodstreams with diseases such as leukemia and lymphoma using an intravenous injection of the radioactive isotope astatine-211 (At-211). The work, its challenges, and its promise were described in a recent news release from the National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program.

To continue reading, log in or create a free account!

Related Articles

NRIC’s DOME “open for business”

April 10, 2026, 2:03PMNuclear News

On Wednesday, Idaho National Laboratory announced that the National Reactor Innovation Center’s Demonstration of Microreactor Experiments (DOME) test bed is now “open for business.” With...

The DOE’s plan for AI in NRC licensing

April 2, 2026, 9:40AMNuclear News

The Department of Energy announced the completion of a proof-of-concept demonstration of the use of Everstar’s AI tool to generate chapter 5 of an NRC license application from preliminary...